Explore cutting-edge studies in tumor biology, molecular pathways, and clinical breakthroughs
A comprehensive look at the phase 1 study of voruciclib for relapsed/refractory AML and B-cell malignancies, exploring CDK9 inhibition as a strategy to overcome treatment resistance.